From the Business News

(yes, I understand this report is for companies with the funds to obtain it; I just think the whole idea is symptomatic of what is wrong with our health illness system.)

http://www.companiesandmarkets.com/S...ease-63862.asp

Cost: $1338.00

Central Nervous System Parkinson Disease (Life Science Analytics)

Market: Healthcare and Medical
Published Date: 08/01/2009
Report Title: Central Nervous System Parkinson Disease

Report Type: Market Report
Country: Global
Number of Pages: 342
Life Science Analytics', Central Nervous System Parkinson Disease contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of parkinson disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

i hope it has a lifetime of updates included - it will be out of date in 6 months.. or maybe tomorrow.

paula

These publications are also typically marketed to investors trying to size various markets. Of course since MJFF allocates capital with building the pipeline in mind, we are monitoring these numbers. MJFF does receive some reports and finds they are often incomplete vis-a-vis our working knowledge of activities -- for instance, reports often don't mention MJFF-funded projects at companies despite the fact that our press releases put the information in the public domain and releases are often a primary source input for such publications.

Anyway, my point is that MJFF typically knows this information and shares these snapshots at research roundtables.

I hope this is helpful.

Best, Debi

According to an outline of what is in this report [sounds like it could be the same one as yours madelyn or similar.]

Is this why Merck is trying to get top dollar now for their brand name sinemet?

Highlights

Stalevo's clear convenience and compliance benefit will see the combination therapy emerge as the market leading brand between 2011 and 2013.


Although Boehringer Ingelheim is relatively late to the market with a once-daily reformulation, Mirapex/Sifrol's (pramipexole) dominant share of some geographic markets will facilitate a successful launch in 2010.

Over the 10-year forecast period the US market will lose significance for Parkinson's disease market players as demographic changes and a less competitive commercial environment will see the European and Japanese markets emerge as key generators of growth.


http://www.marketresearch.com/produc...%27s%09disease


Time is not neutral.